

# Advancing MS therapy: Addressing the patient experience



Saturday 19 June 2021 | 13:45–14:45 CEST

## Agenda

- 13:45** **Chair's introduction:  
Next steps for individualising MS care**  
Til Menge, Germany
- 13:53** **Improving interferon beta further:  
Intramuscular peginterferon beta-1a**  
Til Menge, Germany
- 14:05** **Tailoring fumarates to advance clinically  
meaningful outcomes**  
Anne-Katrin Pröbstel, Switzerland
- 14:17** **Enhancing convenience and flexibility with  
subcutaneous natalizumab**  
Bart Van Wijmeersch, Belgium
- 14:30** **Audience Q&A**  
All faculty

[Register for EAN 2021](#)

## Chair and Faculty

### Til Menge (Chair)

Center for Neurology and Neuropsychiatry  
LVR Clinic, Heinrich-Heine Hospital,  
University of Düsseldorf, Düsseldorf, Germany



Prof. Til Menge is an attending neurologist at the Center for Neurology and Neuropsychiatry, LVR Clinic at Heinrich-Heine-University in Düsseldorf, Germany. He is also an adjunct professor in neuroimmunology. Since 2014 he has served as chief attending neurologist and since 2006 he has been head of the National Laboratory for testing neutralising antibodies against interferon-beta at the University of Düsseldorf. In 2019, Prof. Menge was awarded an American Academy of Neurology (AAN) Fellowship. He has participated in numerous clinical trials for MS therapies and has authored several reviews on current and novel treatments for MS. He is also an appointed member of the medical advisory board of the German MS Society.

### Anne-Katrin Pröbstel

Multiple Sclerosis Center, Neurologic Clinic and Policlinic,  
Departments of Medicine, Biomedicine, and Clinical Research,  
University Hospital of Basel, University of Basel, Basel, Switzerland



Anne-Katrin Pröbstel is a Swiss National Science Eccellenza Professor and attending neurologist at the Multiple Sclerosis Center at the University Hospital of Basel. She is head of the Autoimmune Encephalitis Clinic in the Neurology Department and Research Group Leader of the Experimental Neuroimmunology Group at the Department of Biomedicine at the University of Basel, as well as a core member of the Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB). She was recently awarded the Ellerman Award from the Swiss Neurological Society for her work on elucidating B cell functions and microbial contributions in MS and anti-MOG antibody associated disease.

### Bart Van Wijmeersch

Universitair MS Centrum (UMSC), Rehabilitation & MS Centre Overpelt,  
Hasselt University, Hasselt, Belgium



Associate Professor Bart Van Wijmeersch is a neurologist specialised in multiple sclerosis (MS). He is the medical director of the University MS Centre in Pelt where he leads the multidisciplinary MS team. He is also associate professor of Neurology at the University of Hasselt where he is involved in preclinical and clinical MS research at the Biomedical Institute (BIOMED/REVAL). Additionally, Prof. Van Wijmeersch has an educational role in the Faculty of Medicine and Physiotherapy. He is a member of the Belgian Study Group of Multiple Sclerosis and was a co-founder and first president of the ParadigMS Foundation, an organisation dedicated to MS education to help improve clinical care for MS patients. In 2019, he received an honorary award from the Flemish government to acknowledge his scientific work.